Clinical trial
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
NCT00005949 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005949 |
|---|---|
| Title | Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma |
| Official title | Phase II Study of Melanoma Vaccine (NSC #683472/675756, IND #6123) and Low-Dose, Subcutaneous Interleukin-2 in Advanced Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IV Melanoma |
| Intervention type | Biological, Other |
| Interventions | aldesleukin, gp100:209-217(210M) peptide vaccine, laboratory biomarker analysis |
| Enrollment | 50 |
| Start date | Mar 1, 2001 |
| Primary completion | Mar 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: